{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:56:45Z","timestamp":1794895005992,"version":"4.9.1"},"reference-count":33,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease\u2010modifying antirheumatic drugs or received tumor necrosis factor inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In the 52\u2010week, double\u2010blind, placebo\u2010controlled, phase 3 Program for Evaluation of TYK2 Inhibitor (POETYK) PsA\u20102 study (NCT04908189), patients were randomized 3:3:1 to deucravacitinib 6 mg daily, placebo, or apremilast 30 mg twice daily (safety reference arm) through week 16 (W16). From W16 to W52, patients continued receiving deucravacitinib or apremilast or switched from placebo to deucravacitinib. The primary endpoint was American College of Rheumatology 20% improvement in response (ACR20) at W16. Secondary endpoints were analyzed per prespecified order to control for multiplicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 729 patients were randomized (312 deucravacitinib, 312 placebo, 105 apremilast). Significantly more patients achieved ACR20 at W16 with deucravacitinib versus placebo (54.2% vs 39.4%;\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.0002); responses improved beyond W16 and were maintained through W52 (deucravacitinib\u2010deucravacitinib, 62.2%; placebo\u2010deucravacitinib, 67.3%). At W16, significant differences in deucravacitinib versus placebo were observed in hierarchical secondary endpoints of Health Assessment Questionnaire Disability Index, 75% improvement in the Psoriasis Area and Severity Index, 36\u2010Item Short Form Survey Physical Component Summary, and achievement of minimal disease activity. At W16, serious adverse events occurred in 1.0%, 1.9%, and 3.8% of patients receiving placebo, deucravacitinib, and apremilast, respectively. No new safety signals, deaths, or imbalances in cardiovascular events, malignancies, or opportunistic infections occurred through W52.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Deucravacitinib was well tolerated in patients with PsA and demonstrated superior efficacy versus placebo across multiple clinical endpoints and patient\u2010reported outcomes, including functional ability and quality of life. Clinical responses and patient\u2010reported outcomes were maintained through W52.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.70280","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:50:03Z","timestamp":1784537403000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double\u2010Blind, Phase 3\n                    <scp>POETYK PsA<\/scp>\n                    \u20102 Trial"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[{"name":"Providence Swedish Medical Center  Seattle Washington"},{"name":"University of Washington School of Medicine  Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Departments of Medicine, Laboratory Medicine and Pathobiology, and the Institute of Medical Science University of Toronto  Toronto Ontario Canada"},{"name":"Gladman Krembil Psoriatic Arthritis Program, Schroeder Arthritis Institute University Health Network  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"University of California  Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Hospital Universitario Marqu\u00e9s de Valdecilla  Santander Spain"},{"name":"Immunopathology Group, IDIVAL, Department of Medicine and Psychiatry University of Cantabria  Santander Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania  Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan L.","family":"Siegel","sequence":"additional","affiliation":[{"name":"Arthritis and Rheumatism Associates  Rockville Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology The University of Texas Southwestern Medical Center  Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology Peking Union Medical College Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Comprehensive Centers for Inflammation Medicine University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology Kyorin University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze\u2010Koops","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV Ludwig\u2010Maximilians\u2010University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research  Duncansville Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Dokoupilov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology Masaryk University  Brno Czech Republic"},{"name":"Medical Plus, sro  Uhersk\u00e9 Hradi\u0161t\u011b Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences Nagoya City University  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1791-8729","authenticated-orcid":false,"given":"Eric M.","family":"Ruderman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Rheumatology, Feinberg School of Medicine Northwestern University  Chicago Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Plewinski","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejia","family":"Wang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sardinas","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Vritzali","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Boudry Canton of Neuch\u00e2tel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vaile","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb  Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University  Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2021.101694"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.17\u20101\u201065"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.46497\/ArchRheumatol.2024.10710"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003912"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"e_1_2_8_14_1","volume-title":"Package insert","author":"SOTYKTU (deucravacitinib)","year":"2026"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.25251\/skin.10.supp.532"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw173"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00444"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2026.05.029"},{"key":"e_1_2_8_19_1","volume-title":"Prescribing information","author":"OTEZLA (apremilast)","year":"2024"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105807"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190677"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20553"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42391"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043391"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2025.100329"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104840"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2018.03.041"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211555"},{"key":"e_1_2_8_31_1","unstructured":"Long\u2010term safety study of deucravacitinib versus ustekinumab in participants with psoriasis (PRAGMATYK).ClinicalTrials.gov. Accessed June 26 2026.https:\/\/clinicaltrials.gov\/study\/NCT07116967"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab774"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-022-00485-2"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2452054"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70280","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.70280","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.70280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:40:01Z","timestamp":1790563201000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.70280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":33,"alternative-id":["10.1002\/art.70280"],"URL":"https:\/\/doi.org\/10.1002\/art.70280","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"2026-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"art.70280"}}